Alkermes plc. Finite-Lived Intangible Asset, Expected Amortization, Year Four
Alkermes plc. (ALKS) had Finite-Lived Intangible Asset, Expected Amortization, Year Four of $115.70 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour · last filed 2026-07-28
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year Four $115.70M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $115.60M.
- 2021-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $1.00M.
- 2020-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $1.00M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Four |
|---|---|
| 2026-06-30 | $115.70M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $115.60M 10-Q · filed 2026-05-05 |
| 2021-12-31 | $1.00M 10-K · filed 2022-02-16 |
| 2020-12-31 | $1.00M 10-K · filed 2021-02-11 |
| 2020-09-30 | $1.00M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $35.00M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $35.00M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $35.00M 10-K · filed 2020-02-13 |
| 2019-09-30 | $35.00M 10-Q · filed 2019-10-23 |
| 2019-06-30 | $35.00M 10-Q · filed 2019-07-25 |
| 2019-03-31 | $35.00M 10-Q · filed 2019-04-25 |
| 2018-12-31 | $35.00M 10-K · filed 2019-02-15 |
| 2018-09-30 | $40.00M 10-Q · filed 2018-10-23 |
| 2018-06-30 | $40.00M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $40.00M 10-Q · filed 2018-04-26 |
| 2017-12-31 | $40.00M 10-K · filed 2018-02-16 |
| 2017-09-30 | $50.00M 10-Q · filed 2017-10-26 |
| 2017-06-30 | $50.00M 10-Q · filed 2017-07-27 |
| 2017-03-31 | $50.00M 10-Q · filed 2017-04-27 |
| 2016-12-31 | $50.00M 10-K · filed 2017-02-17 |
| 2016-09-30 | $55.00M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $55.00M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $55.00M 10-Q · filed 2016-04-28 |
| 2015-12-31 | $55.00M 10-K · filed 2016-02-25 |
| 2015-09-30 | $60.00M 10-Q · filed 2015-10-29 |
| 2015-06-30 | $60.00M 10-Q · filed 2015-07-30 |
| 2015-03-31 | $60.00M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $70.00M 10-K · filed 2015-02-24 |
| 2014-09-30 | $70.00M 10-Q · filed 2014-10-29 |
| 2014-06-30 | $70.00M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $70.00M 10-Q · filed 2014-04-30 |
| 2013-12-31 | $70.00M 10-KT · filed 2014-02-27 |
| 2013-09-30 | $70.00M 10-Q · filed 2013-10-31 |
| 2013-06-30 | $70.00M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $70.00M 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |